Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

uPAR-PET for Prognostication in Patients With Non-small Cell Lung Cancer, Malignant Pleural Mesothelioma and Large Cell Neuroendocrine Carcinoma of the Lung

NCT02755675 is registered in ClinicalTrials.gov with Rigshospitalet, Denmark as lead sponsor.

NCT NCT02755675
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02755675 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
uPAR-PET for Prognostication in Patients With Non-small Cell Lung Cancer, Malignant Pleural Mesothelioma and Large Cell Neuroendocrine Carcinoma of the Lung
Lead sponsor
Rigshospitalet, Denmark
Phase
Phase 2
Overall status
Unknown status
Start date
April 30, 2016
Completion date
October 31, 2023
Enrollment
120 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

large cell neuroendocrine carcinoma of the lung, malignant pleural mesothelioma, non-small cell lung cancer